covanc dx stabl
upsid option upgrad buy
upgrad labcorp lh buy hold buy rate reflect
increasingli construct view covanc contract research busi coupl
belief risk diagnost skew upsid
view covanc improv see opportun
recent industri check support covanc opportunity/strate-
gy industri data suggest continu healthi oper environ more-
posit view envigo asset swap note well
increas appreci margin opportun covanc
headwind tailwind diagnost damag contain
lh diagnost sale face headwind reimburse-
ment cut share loss associ open larg nation manag
care contract quest risk seem contain follow
print remain skeptic broader organ inorgan share gain opportu-
niti diagnost highlight recent note support
check sinc said believ skeptic bake number could see
upsid effort like unitedhealthcar prefer lab network pln genuin
lead volum shift lh stand benefit expand guidelin non-invas
prenat test nipt someth still think could happen year estimate
sale nipt moreov could cusp improv trend
healthcar util trend suggest data db hospit reve-
nue tracker benefit nation lab
increas pt
price target lh reflect enterpris valu use project level debt
cash ebitda ex option multipl dis-
count reflect organ growth price headwind face
compani increas multipl compar prior view ebitda
reflect greater convict busi well improv market multipl
price jun usd
hold buy
risk pressur lab test price
util specif downturn
healthcar util
gener motiv either reduc
access health insur and/or high
continu hospit acquisit physician
offic practic associ in-sourc
lab test volum dissemin
test away refer lab
associ point-of-car test
deutsch bank seek busi compani cover research report thu investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis disclosur analyst certif locat
distribut gmt
recent check data support
recent check custom supplier competitor construct
covanc lab data contract research strategi competitor specif
flag covanc data advantag custom proactiv highlight data
contract research offer compel supplier posit
covanc strategi vs contract research organ
commentari anecdot cours direct consist
sentiment express blind survey senior clinic pharma executives/
influenc conduct iqvia april shown covanc rank
like bring innov transform healthcar
figur covanc like bring innov transform healthcar
blind survey senior clinic commerci pharma executives/influenc conduct iqvia april
moreov time american societi clinic oncolog annual
meet earlier month left us bullish opportun covanc
busi biomark test submit abstract refer
biomark biomarker-driven therapi continu becom larger part
therapeut develop commerci landscap shown chart
number fda-approv oncolog drug biomark label
respond june
figur oncolog drug biomark label grown
mckinsey present fda pharmacogenom biomark drug label
on-going phase oncolog trial includ biomark assess
estim biomark test busi covanc revenu
grow expect strong double-digit growth
continu support book bill believ biomark test could
add increment organ covanc growth
macro backdrop support continu end market health
though date capit rais drug approv lower prior year
indic remain strong rel histori
biocenturi includ ventur follow-on ipo
fda to-dat number june
number approv oncolog per per capit rais new drug approv june
biocenturi includ ventur follow-on ipo
figur number pipelin drug acceler
increasingli construct covanc margin opportun
covanc oper margin remain well peer illustr tabl
said covanc remain commit attain peer margin translat
someth low given mix busi signific upsid
low mid-teen rate contempl guidanc expect margin
improv come number sourc includ facil consolid
move low cost region feasibl complet envigo asset swap
improv price earli develop covanc sale mix contin-
 execut launchpad initi
diagnost headwind outweigh tailwind see
headwind well known seem contain
volum headwind manag care exclus loss horizon
sever expect lh commun share loss
stabil februari stabil persist year expect
believ upsid might possibl vs lh initi guidanc assumpt
sever opportun upsid option nipt higher healthcar
util among
dilig make us skeptic enhanc steer effort man-
age care drive volum lh lh competitor auction dis-
tress price see upsid wrong also continu expect
american colleg obstetrician gynecologist acog endors averag
risk cell-fre dna cfdna nipt year endors believ key
unlock broader reimburs coverag estim nipt compris
lh sale today see opportun volum doubl broader reimburse-
separ db hospit revenu tracker suggest could see uptick
healthcar util benefit lh test volum april data
db hospit revenu tracker healthcar system indic
util solid start store sale y/i vs y/i
impress particularli difficult flu comp
period end cost oper expens expens incom expens ep share share growth sale out-of-pocket net restat cash flowoper cash cash cash
period end asset equival st receiv expens current current equip asset asset liabil current portion long-term current debt less current long-term liabil stockhold june
